NGNE
Neurogene Inc.
Healthcare — Biotechnology
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Price History
Fundamentals
| Market Cap | $535.37M |
| P/E Ratio (TTM) | - |
| Forward P/E | -6.06 |
| EPS (TTM) | $-4.55 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -37.25% |
| Debt/Equity | 3.84 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $81.00 |
| Analysts | 7 |
| Next Earnings | Aug 11, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 72.7 |
| Beta | 2.04 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $37.27 |
| 52-Week Low | $15.93 |
| 50-Day Avg | $28.97 |
| 200-Day Avg | $23.63 |
| Avg Volume | 180.0K |
| Volume | 677.2K |
Performance Analysis
NEUTRALNGNE presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:22 UTC
Back to Screener Export Report